Supernus Pharmaceuticals buy tamam
Start price
15.06.17
/
50%
€34.55
Target price
06.11.19
€61.34
Performance (%)
-46.16%
End price
06.11.19
€18.60
Summary
This prediction ended on 06.11.19 with a price of €18.60. The BUY prediction by tamam for Supernus Pharmaceuticals performed very badly with a performance of -46.16%. tamam has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Supernus Pharmaceuticals | -8.392% | -8.392% | -16.561% | 5.645% |
| iShares Core DAX® | -0.051% | 4.829% | 17.062% | 18.811% |
| iShares Nasdaq 100 | 1.659% | 2.417% | 38.705% | 56.555% |
| iShares Nikkei 225® | 0.658% | -2.173% | 13.159% | 7.768% |
| iShares S&P 500 | 0.964% | 2.547% | 30.492% | 47.355% |
Comments by tamam for this prediction
In the thread Supernus Pharmaceuticals diskutieren
Supernus is still well positioned to grow into the future.
Supernus has delivered solid gains to its shareholders over the last few years and I believe it is still well positioned to grow well into the future.
I believe SUPN is an attractive takeover target, especially now that we have a high degree of certainty regarding their IP on Trokendi and Oxtellar. And the pipeline is probably more valuable than the marketed portfolio in the long run. With the stock price heading where it should be, the company might start to consider offers.
Stopped prediction by tamam for Supernus Pharmaceuticals
Supernus Pharmaceuticals
Start price
Target price
Perf. (%)
€18.10
06.11.19
06.11.19
€32.00
04.11.21
04.11.21
51.38%
05.11.21
05.11.21
